These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32972393)

  • 1. Beyond clinical outcomes: the social and healthcare system implications of hepatitis C treatment.
    Torrens M; Soyemi T; Bowman D; Schatz E
    BMC Infect Dis; 2020 Sep; 20(1):702. PubMed ID: 32972393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era.
    Valerio H; McAuley A; Innes H; Palmateer N; Goldberg DJ; Munro A; Taylor A; Hutchinson SJ
    Int J Drug Policy; 2018 Feb; 52():115-122. PubMed ID: 29414462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment cascade for hepatitis C virus in young adult people who inject drugs in San Francisco: Low number treated.
    Morris MD; Mirzazadeh A; Evans JL; Briceno A; Coffin P; Hahn JA; Page KA
    Drug Alcohol Depend; 2019 May; 198():133-135. PubMed ID: 30921649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High prevalence of HIV, HBsAg and anti-HCV positivity among people who injected drugs: results of the first bio-behavioral survey using respondent-driven sampling in two urban areas in Mozambique.
    Semá Baltazar C; Horth R; Boothe M; Sathane I; Young P; Chitsondzo Langa D; Condula M; Ricardo H; Dengo Baloi L; Cummings B; Schaad N; Gouveia L; Teodoro E; Raymond HF
    BMC Infect Dis; 2019 Dec; 19(1):1022. PubMed ID: 31791273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries.
    Maticic M; Zorman JV; Gregorcic S; Schatz E; Lazarus JV
    Harm Reduct J; 2019 May; 16(1):32. PubMed ID: 31072401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knowledge of hepatitis C and treatment willingness amongst people who inject drugs in an era of direct acting antivirals.
    Mah A; Hull MW; DeBeck K; Milloy MJ; Dobrer S; Nosova E; Wood E; Kerr T; Hayashi K
    Int J Drug Policy; 2017 Sep; 47():137-143. PubMed ID: 28347636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).
    Wenz B; Nielsen S; Gassowski M; Santos-Hövener C; Cai W; Ross RS; Bock CT; Ratsch BA; Kücherer C; Bannert N; Bremer V; Hamouda O; Marcus U; Zimmermann R;
    BMC Public Health; 2016 Sep; 16(1):927. PubMed ID: 27595567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.
    Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J;
    Int J Drug Policy; 2015 Oct; 26(10):976-83. PubMed ID: 26115881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries.
    Maticic M; Videcnik Zorman J; Gregorcic S; Schatz E; Lazarus JV
    BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S14. PubMed ID: 25252635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
    Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J;
    Int J Drug Policy; 2017 Sep; 47():230-238. PubMed ID: 28633998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.
    Butler K; Day C; Dietze P; Bruno R; Alati R; Burns L
    J Subst Abuse Treat; 2015 Nov; 58():90-4. PubMed ID: 26117080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
    Kåberg M; Hammarberg A; Lidman C; Weiland O
    Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C bio-behavioural surveys in people who inject drugs-a systematic review of sensitivity to the theoretical assumptions of respondent driven sampling.
    Buchanan R; Khakoo SI; Coad J; Grellier L; Parkes J
    Harm Reduct J; 2017 Jul; 14(1):44. PubMed ID: 28697760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engaging people who inject drugs in hepatitis C virus testing and prevention through community-based outreach, in Sydney, Australia.
    Coupland H; White B; Bates A; Park JN; Iversen J; Maher L
    Drug Alcohol Rev; 2019 Feb; 38(2):177-184. PubMed ID: 30652363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs.
    Childs E; Assoumou SA; Biello KB; Biancarelli DL; Drainoni ML; Edeza A; Salhaney P; Mimiaga MJ; Bazzi AR
    Harm Reduct J; 2019 Feb; 16(1):14. PubMed ID: 30744628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
    Rahman M; Janjua NZ; Shafiq TKI; Chowdhury EI; Sarker MS; Khan SI; Reza M; Faruque MO; Kabir A; Anis AH; Azim T
    Int J Drug Policy; 2019 Dec; 74():69-75. PubMed ID: 31542689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection.
    Artenie AA; Zang G; Daniel M; Fortier E; Jutras-Aswad D; Puzhko S; Bruneau J
    Int J Drug Policy; 2017 Sep; 47():239-243. PubMed ID: 28587944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?
    Panagiotoglou D; Krebs E; Min JE; Olding M; Ahamad K; Ti L; Montaner JSG; Nosyk B
    Int J Drug Policy; 2017 Sep; 47():169-176. PubMed ID: 28578865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.
    Iversen J; Grebely J; Topp L; Wand H; Dore G; Maher L
    J Viral Hepat; 2014 Mar; 21(3):198-207. PubMed ID: 24438681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.
    Socías ME; Ti L; Wood E; Nosova E; Hull M; Hayashi K; Debeck K; Milloy MJ
    Liver Int; 2019 Aug; 39(8):1400-1407. PubMed ID: 30653809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.